News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
September 02, 2021Dr. Adi Mor continues as Chief Scientific Officer, directing scientific strategy and overseeing R&D operations-
September 01, 2021
- Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business UpdateAugust 13, 2021- CM-101 Phase 2a trials in PSC and liver fibrosis continue to enroll patients with data expected in 2022 -
-
June 23, 2021AGC Biologics to manufacture CM-101 for Phase II/III trials at their Copenhagen facility
-
May 13, 2021Announced positive data from its Phase Ib SPARK study evaluating CM-101 in NAFLD patients
-
April 26, 2021The study aims to further validate the anti-fibrotic and anti-inflammatory activity of CM-101 while providing safety and PK data to support development of the subcutaneous formulation
-
March 16, 2021Shares of Chemomab Therapeutics to commence trading on the Nasdaq Capital Market on March 17, 2021 under the new ticker symbol "CMMB"